Topics

Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Melanoma,Hodgkin Disease,Carcinoma, Renal Cell,Carcinoma, Non-Small-Cell Lung, Date of authorisation: 19/06/2015, Revision: 28, Status: Authorised

13:00 EDT 28 Oct 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Melanoma,Hodgkin Disease,Carcinoma, Renal Cell,Carcinoma, Non-Small-Cell Lung, Date of authorisation: 19/06/2015, Revision: 28, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Melanoma,Hodgkin Disease,Carcinoma, Renal Cell,Carcinoma, Non-Small-Cell Lung, Date of authorisation: 19/06/2015, Revision: 28, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Melanoma,Hodgkin Disease,Carcinoma, Renal Cell,Carcinoma, Non-Small-Cell Lung, Date of authorisation: 19/06/2015, Revision: 28, Status: Authorised"

Quick Search

Relevant Topics

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...

Renal disease
Chronic kidney disease (CKD), also known as chronic renal disease, is a progressive loss in renal function over a period of months or years. The symptoms of worsening kidney function are non-specific, and might include feeling generally unwell and experi...